Andrew Callos

EVP, Chief Commercial Officer at Cytokinetics

Andrew joined us as Executive Vice President, Chief Commercial Officer in March 2021.

Andrew has a deep biopharma background which includes well over 20 years at Pfizer and Wyeth Pharmaceuticals, including roles of increasing responsibility overseeing US and International pharmaceutical franchises. Most recently Andrew served as Regional President and General Manager North America, Upjohn Business Unit at Pfizer. Prior to this role and during his 11+ years at Pfizer, he held several leadership positions including Vice President U.S. Cardiology & Metabolic Marketing where he led the commercialization of Eliquis in the U.S., Vice President and Head of Inflammation Marketing Europe and Vice President Global Commercial Development Rare Disease. Prior to Pfizer, Andrew spent over 10 years at Wyeth Pharmaceuticals in various roles within Business Planning & Analysis, ultimately serving as AVP Marketing across several products. Andrew started the first 7 years of his career as a Consulting Manager at Accenture.

Andrew received a B.S. in Commerce and Engineering from Drexel University.

Location

Philadelphia, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Cytokinetics

15 followers

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators as potential treatments for people with diseases characterized by impaired or declining muscle function.


Industries

Employees

201-500

Links